The danish PEP registry: Experience with the use of postexposure prophylaxis (PEP) following sexual exposure to HIV from 1998 to 2006

Sexually Transmitted Diseases

Volumn 37, Issue 1, 2010, Pages 49-52

  Lunding, Suzanne ^a   Katzenstein, Terese L ^b   Kronborg, Gitte ^c   Lindberg, Jens A ^d   Jensen, Janne ^e   Nielsen, Henrik I ^f   Pedersen, Court ^g   Jørgensen, Louise B ^h  

^a Nordsjællands Hospital Hillerød   (Denmark)

^b University of Copenhagen   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e KOLDING HOSPITAL   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ANUS INTERCOURSE; ARTICLE; CONDOM; CONTROLLED STUDY; DENMARK; DISEASE ACTIVITY; DISEASE REGISTRY; DRUG EXPOSURE; EJACULATION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PATIENT COMPLIANCE; PRESCRIPTION; PROPHYLAXIS; QUESTIONNAIRE; REGISTER; SEROCONVERSION; SEXUAL ORIENTATION; SEXUALITY; STRUCTURED QUESTIONNAIRE; VIRUS LOAD; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DENMARK; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RAPE; SEXUAL BEHAVIOR;

EID: 74249086334     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181b6f284     Document Type: Article

References (29)

1. Katz MH, Gerberding JL. The care of persons with recent sexual exposure to HIV. Ann Intern Med 1998; 128:306-312.
2. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV-seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337:1485-1490.
3. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (Human Immunodeficiency Virus type 2). J Virol 2000; 74:9771-9775.
4. Tsai C, Emau P, Follis KE, et al. Effectiveness of post inoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-4273.
5. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339:1409-1414.
6. Poynten IM, Smith DE, Cooper DA, et al. The public health impact of widespread availability of nonoccupational postexpo-sure prophylaxis against HIV. HIV Med 2007; 8:374-381.
7. Sonder GJB, van den Hoek A, Regez RM, et al. Trends in HIV postexposure prophylaxis prescription and after sexual exposure in Amsterdam, 2000-2004. Sex Transm Inf 2007; 34:288-293.
8. Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35:519-525.
9. Laporte A, Jourdan N, Bouvet E, et al. Post-exposure prophylaxis after non-occupational HIV exposure: Impact of recommendations on physicians' experiences and attitudes. AIDS 2002; 16: 397-405.
10. Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study. J Infect Dis 2001; 183:707-714.
11. Pinkerton SD, Martin JN, Roland ME, et al. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004; 164: 46-54.
12. Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. AIDS 1998; 12:1067-1078.
13. Herida M, Larsen C, Lot F, et al. Cost-effectiveness of HIV post-exposure prophylaxis in France. AIDS 2006; 20:1753-1761.
14. Giele CM, Maw R, Carne CA, et al. Post-exposure prophylaxis for non-occupational exposure to HIV: Current clinical practice and opinions in the UK. Sex Transm Inf 2002; 78:130-132.
15. Cowan SA, Smith E. Forekomsten af HIV/AIDS i Danmark i perioden 1990-2005. Ugeskr Laeger 2006; 168:2247-2252.
16. Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. Ann Intern Med 1990; 113: 740-746.
17. Greub G, Gallant S, Zurn P, et al. Spare non-occupational HIV post-exposure prophylaxis by active contacting and testing of the source person. AIDS 2002; 16:1171-1176.
18. Haff J, Cowan S. Sexlivsundersøgelsen 2006. Stop AIDS og Statens Serum Institut, Department of Epidemiology, Copenhagen, Denmark 2007.
19. Halgreen T, Kristensen JG. Sexlivsundersøgelsen 2000. Stop AIDS og Statens Serum Institut, Department of Epidemiology, Copenhagen, Denmark 2002.
20. Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post-and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immun Defic Syndr 2008; 47:241-247.
21. de Silva S, Miller RF, Walch J. Lack of awareness of HIV post-exposure prophylaxis among HIV-infected and uninfected men attending an inner London clinic. Int J STD AIDS 2006; 17:629-630.
22. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18:787-792.
23. Loutfy MR, Macdonald S, Myhr T, et al. Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors. Antivir Ther 2008; 13:87-95.
24. Rey D, Marc KB, Bouhnik A, et al. Physicians and patients adherence to antiretroviral prophylaxis after sexual exposure to HIV: Results from South-Eastern France. AIDS care 2008; 20: 537-541.
25. Worm AM, Sidenius K, Worm SW, et al. HIV post exposure prophylaxis after sexual assault. In: XVIII FIGO World Congress of Gynecology and Obstetrics; 2006. Kuala Lumpur, Malaysia. Abstract.
26. Almeda J, Casabona J, Simon B, et al. Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe. Euro Surveill 2004; 9:35-40.
27. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after injection-drug use, or other nonoccupational exposures to HIV in the United States. MMWR 2005; 54(RR-2):1-20.
28. Kim JC, Martin LJ, Denny L. Rape and post-exposure prophylaxis: Addressing the dual epidemics in South Africa. Reprod Health Matters 2003; 11:101-112.
29. Kim JC, Askew I, Muvhango L, et al. Comprehensive care and HIV prophylaxis after sexual assault in rural South Africa: The Refentse intervention study. BMJ 2009; 338:b515.